Intercept Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Intercept Pharmaceuticals Il CEO è Jerry Durso, nominato in Jan2021, e ha un mandato di 2.83 anni. la retribuzione annua totale è $ 4.46M, composta da 16% di stipendio e 84% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di $ 984.47K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 8.7 anni.
Informazioni chiave
Jerry Durso
Amministratore delegato
US$4.5m
Compenso totale
| Percentuale dello stipendio del CEO | 16.0% |
| Mandato del CEO | 2.8yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 2.7yrs |
| Durata media del Consiglio di amministrazione | 8.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$159m |
| Mar 31 2023 | n/a | n/a | -US$173m |
| Dec 31 2022 | US$4m | US$715k | -US$175m |
| Sep 30 2022 | n/a | n/a | -US$202m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$8m | US$691k | -US$136m |
| Sep 30 2021 | n/a | n/a | -US$144m |
| Jun 30 2021 | n/a | n/a | -US$193m |
| Mar 31 2021 | n/a | n/a | -US$231m |
| Dec 31 2020 | US$4m | US$600k | -US$273m |
| Sep 30 2020 | n/a | n/a | -US$321m |
| Jun 30 2020 | n/a | n/a | -US$339m |
| Mar 31 2020 | n/a | n/a | -US$347m |
| Dec 31 2019 | US$4m | US$573k | -US$345m |
| Sep 30 2019 | n/a | n/a | -US$335m |
| Jun 30 2019 | n/a | n/a | -US$314m |
| Mar 31 2019 | n/a | n/a | -US$318m |
| Dec 31 2018 | US$3m | US$541k | -US$309m |
| Sep 30 2018 | n/a | n/a | -US$333m |
| Jun 30 2018 | n/a | n/a | -US$341m |
| Mar 31 2018 | n/a | n/a | -US$352m |
| Dec 31 2017 | US$4m | US$441k | -US$360m |
Compensazione vs Mercato: La retribuzione totale di Jerry ($USD 4.46M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.19M ).
Compensazione vs guadagni: La retribuzione di Jerry è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Jerry Durso (55 yo)
2.8yrs
Mandato
US$4,455,463
Compensazione
Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.8yrs | US$4.46m | 0.12% $ 984.5k | |
| Chief Financial Officer | 2.4yrs | US$1.39m | 0.055% $ 437.4k | |
| General Counsel | 2.8yrs | US$1.31m | 0.13% $ 1.1m | |
| Executive VP & Chief Commercial Officer | 2.8yrs | US$1.34m | 0.040% $ 317.4k | |
| President of Research & Development and Chief Medical Officer | 2.4yrs | US$1.61m | 0.068% $ 538.6k | |
| Chief Accounting Officer & Treasurer | 2.7yrs | US$856.23k | 0.061% $ 483.6k | |
| Executive Director of Global Investor Relations | 1.9yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 6.5yrs | US$1.91m | 0.036% $ 285.7k | |
| Founder | 2.8yrs | US$6.43m | 1.48% $ 11.8m | |
| Senior Vice President of Regulatory Affairs | no data | Nessun dato | Nessun dato | |
| Chief Quality Officer & SVP of Technical Operations | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Corporate Affairs | less than a year | Nessun dato | Nessun dato |
2.7yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di ICPT è considerato esperto (durata media dell'incarico 2.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.5yrs | US$4.46m | 0.12% $ 984.5k | |
| Founder | 21.8yrs | US$6.43m | 1.48% $ 11.8m | |
| Independent Chairman | 7.3yrs | US$327.39k | 0.056% $ 447.4k | |
| Independent Director | 9.8yrs | US$332.39k | 0.056% $ 445.5k | |
| Independent Director | 9.3yrs | US$327.39k | 0.061% $ 484.3k | |
| Independent Director | 11.1yrs | US$317.39k | 0.091% $ 719.8k | |
| Lead Independent Director | 8yrs | US$337.39k | 0.057% $ 449.2k | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 7.3yrs | US$322.39k | 0.059% $ 469.7k |
8.7yrs
Durata media
62yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ICPT sono considerati esperti (durata media dell'incarico 8.7 anni).